key: cord-0307634-reyb9kg4 authors: Song, Yujing; Zhao, Jingyang; Cai, Tao; Su, Shiuan-Haur; Sandford, Erin; Flora, Christopher; Singer, Benjamin H.; Ghosh, Monalisa; Choi, Sung Won; Tewari, Muneesh; Kurabayashi, Katsuo title: Machine Learning-Based Protein Microarray Digital Assay Analysis date: 2020-08-04 journal: bioRxiv DOI: 10.1101/2020.08.04.236448 sha: 3a946692e0a64d1ea5844b320cfd1a12ac41f5f2 doc_id: 307634 cord_uid: reyb9kg4 Serial measurement of a large panel of protein biomarkers near the bedside could provide a promising pathway to transform the critical care of acutely ill patients. However, attaining the combination of high sensitivity and multiplexity with a short assay turnaround poses a formidable technological challenge. Here, we developed a rapid, accurate, and highly multiplexed microfluidic digital immunoassay by incorporating machine learning-based autonomous image analysis. The assay achieved 14-plexed biomarker detection at concentrations < 10pg/mL with a sample volume < 10 μL, including all processes from sampling to analyzed data delivery within 30 min, while only requiring a 5-min assay incubation. The assay procedure applied both a spatial-spectral microfluidic encoding scheme and an image data analysis algorithm based on machine learning with a convolutional neural network (CNN) for pre-equilibrated single-molecule protein digital counting. This unique approach remarkably reduced errors facing the high-capacity multiplexing of digital immunoassay at low protein concentrations. Longitudinal data obtained for a panel of 14 serum cytokines in human patients receiving chimeric antigen receptor-T (CAR-T) cell therapy manifested the powerful biomarker profiling capability and great potential of the assay for its translation to near-real-time bedside immune status monitoring. Over the past few years, the approach of providing personalized treatment for severely ill patients based on their individualized molecular profiles has received considerable attention as a next step to advance critical care medicine (1-3). Progress has been made in identifying predictive and prognostic protein biomarkers in critical care which holds great promise in patient stratification (4, 5) , disease monitoring (6, 7) , and therapy development (3, 8) . For example, Cao et al (9) tested patients infected with the 2019 novel coronavirus (COVID- 19) and reported that a panel of eight plasma cytokines showing significantly heightened levels allowed them to distinguish a group of severely ill patients from a group of mildly ill patients. However, even with the discoveries of these biomarkers, the medical community still falls behind with adopting the precision medicine approach to treat life-threatening acute illnesses, such as cytokine release syndrome (CRS), acute respiratory distress syndrome (ARDS), which are frequently associated with the 2019 novel coronavirus (COVID- 19) , (9, 10) due to the lack of a sensitive molecular profiling tool to quickly guide clinical decisions or interventions with a near-real-time assay turnaround (1). Additionally, to monitor the highly heterogeneous and time-pressing illness conditions, high multiplex capacity is equally important as sensitivity and speed for improving diagnosis and prognosis accuracy with rich, comprehensive information on multiple biomarker profiles (1, 9, 11, 12) . Currently, the commonly used clinical tools for multiplex serum/plasma protein analysis (13) , including the bead-based assay coupled flow cytometry and the western blot, fall short of achieving the performance needed for critical care as they require a long assay time (>4 hrs), and laborious steps with limited sensitivity. Researchers have developed rapid (14) (15) (16) (17) , point-of-care (18) (19) (20) , multiplex (21, 22) immunoassays powered by microfluidics. Nonetheless, it is still challenging for these assays to simultaneously achieve a combination of high multiplexity and sensitivity with a rapid assay turnaround time in a clinical setting. By counting single-molecule reactions in fL-nL-volume microwells or droplets (23) (24) (25) , digital immunoassays can provide unprecedented sensitivity (sub-fM detection) for biomarker analysis. Our recent study (26) demonstrated that it is feasible to extend the digital assay approach to achieve near-realtime protein biomarker profiling at a clinically relevant pM-nM range by quenching reagent reaction at an early pre-equilibrium stage with an incubation process as short as 15-300 sec. However, existing digital immunoassay platforms (27) have limited multiplex capacity (up to 6-plex). The current method (24, 28) utilizes fluorescence dye-encoded beads to identify different analytes. Unfortunately, the nature of binary-based statistical counting brings a few critical challenges to multiplexing digital immunoassays with this method. First, the assay typically requires a large number of beads (e.g. Simoa uses 100,000 beads per plex (27) ) for reliable analyte quantification. Mixing and counting such a large number of multi-color-encoded beads tends to cause false signal recognition due to optical crosstalk or non-uniform color coating. Second, increasing multiplexity while keeping the assay's sensitivity and accuracy additionally requires a large number of microwell arrays to accommodate the large number of beads. This becomes impractical with the current platform as it demands a significantly increased assay device footprint and an image area size. Third, the assay also encounters a significant bead loss during the digitization process partitioning the beads into sub-volumes after the initial reaction process performed for bulk reagent volume in a cuvette (100 µL). All of these issues prohibit the translation of a cheap, robust, point-of-care multiplexed digital assay platform into near-patient applications, thus necessitating a new strategy. Here, we have developed a highly multiplexed digital immunoassay platform, termed the "pre-equilibrium digital enzyme-linked immunosorbent assay (PEdELISA) microarray." The PEdELISA microarray analysis integrates on-chip biosensors with a small footprint to minimize the number of images that are needed to read and fully automates the signal counting process, both of which are critically necessary for overcoming the bottlenecks against multiplexing digital assays. The analysis incorporates a powerful microfluidic spatial-spectral encoding method and a machine learning-based image processing algorithm into multi-biomarker detection. The spatial-spectral encoding method confines color-encoded magnetic beads into the arrayed patterns of microwells on a microfluidic chip. The locations of the microwell patterns on the chip indicate which target analytes are detected by trapped color-coded beads. In contrast to the existing digital immunoassay protocol, the fully integrated microfluidic architecture allows the assay reaction to be performed entirely on-chip (no bead loss) at an early pre-equilibrium state, which only requires a sample volume < 10 µL, a 5-min assay incubation and a 75 mm × 50 mm chip size. Based on a convolutional neural network (CNN), the machine learning algorithm permits unsupervised image data analysis while resolving false signal recognition accompanying the multiplexing of digital immunoassays. Employing these biosensing schemes, the PEdELISA microarray platform allows us to simultaneously quantify a large panel of biomarkers in half an hour without sacrificing the accuracy. We used the platform to obtain longitudinal data for blood samples from human patients experiencing cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy. The data signify the time-course evolution of the profiles of 14 circulating cytokines over illness development. With its near-real-time assay turnaround and analytical power, the platform manifests great potential to enable acute immune disorder monitoring that guides timely therapeutic interventions. Multiplexed Digital Immunoassay with CNN Image Processing. The PEdELISA microarray analysis used a microfluidic chip fabricated using polydimethylsiloxane (PDMS)-based soft lithography. The chip contains parallel sample detection channels (10-16) on a glass substrate, each with an array of hexagonal biosensing patterns ( Figure 1A ). The hexagonal shape allows each biosensing pattern to densely pack 43,561 fL-sized microwells, which fits into the entire field of view of a full-frame CMOS sensor through a 10x objective lens ( Figure S1 ). Prior to the assay, we deposited magnetic beads (d = 2.8 μm) encoded with non-fluorescent color (no color) and those with Alexa Fluor® 488 (AF 488) into physically separated microwell arrays ( Figure S2 ). These beads were conjugated with different capture antibodies according to their colors and locations on the chip. In the current design, the arrangement of 2 colors and 8 arrayed biosensing patterns in each detection channel allows the PEdELISA microarray chip to detect 2 × 8 = 16 protein species (16-plex) at its maximum capacity for each sample loaded to the detection channel. Compared with a single color-encoded method, this combination greatly reduces potential optical crosstalk and fluorescence overlap during a signal readout process. The predeposition ensures a fixed number of beads to target each biomarker, which allows more accurate digital counting for each biomarker. It also eliminates bead loss during the conventional partition process and achieves nearly a 100% yield in the signal readout for enzyme active QuantaRed TM (Qred)-emitting beads ("On" beads or "Qred+" beads). The microwell structure (diameter: 3.4 µm and depth: 3.6 µm) was designed to generate sufficient surface tension to hold beads in the microwells. This kept false signals resulting from physical crosstalk between the trapped beads at a negligible level ( Figure S3) . A unique challenge posed by highly multiplexed digital assays is to provide fast and accurate analysis of fluorescence signals originating from ~7 million microwells per chip. Additionally, the signal counting process needs to distinguish precisely between images of multi-color bead-filled and empty microwells and to identify signals accurately while subjected to a large fluorescence intensity variance, occasional image defects due to reagent mishandling, and image focus shifts. These challenges make the conventional image processing method with the thresholding and segmentation (GTS) scheme ( Figure S4A ) inaccurate, thus requiring human supervision for error correction in handling digital assay images. Mu et al. (29, 30) showed that the use of machine learning algorithms would provide promising solutions to significantly improve the accuracy of digital assay image processing. However, this approach is only applied for single-color images with a small number of microreactors (a few thousand) with 1080×1120 pixels, which is impractical for high-throughput analysis. To address these challenges, we developed a novel dual-pathway parallel-computing algorithm based on convolutional neural network (CNN) visualization for image processing. The CNN-based analysis procedure ( Figure 1B ) includes multi-color fluorescence image data read-in/pre-processing (image crop, noise filtering, and contrast enhancement), microwell/bead image segmentation by pre-trained dual-pathway CNN, post-processing, and result output. The key component, dual-pathway CNN, was pre-trained to classify and segment image pixels by labels of (I) fluorescence "On" (Qred channel) microwells, (II) Alexa Fluor® 488 color-encoded beads (AF488 channel), (III) image defects, and (IV) background. The architecture of the network ( Figure 1B ) is separated into a downsampling process for category classification and an upsampling process for pixel segmentation. The downsampling process consists of 3 layers, including 2 convolution layers (4-6 filters, kernel of 3×3) with a rectified linear unit (ReLU), and a max-pooling layer (stride of 2) in between. The upsampling process consists of a transposed convolution layer with ReLU, a softmax layer and a pixel classification layer. To speed up the training process, we started with dividing an image with 32 × 32 pixels and classifying them with the labels and then eventually expanding the image pixel size to 256 × 256 using a pre-trained network ( Figure S5 ). We found a large intensity variance across the optical signals from beads in different microwell reactors. As a result, the intensity-based labeling of microwells leads to recognition errors. Microwells with bright beads can be misrecognized to have larger areas with more pixels than those with dim beads. Instead, given that all microwells are lithographically patterned to have an identical size, we labeled them using the same prefixed area scale (octagon, r=3 pixel for microwell, disk, r=2 pixel for bead) regardless of their image brightness to make the machine to recognize them correctly. The majority of pixel labels are for the background (Label IV) with no assay information in typical digital assay images. We used the inverse frequency weighting method to further enhance the classification accuracy, which gives more weights to less frequently appearing classes that are identified by Labels (I), (II), and (III) (See Supporting Information and Figure S5 for training details). In contrast to a previously reported study (29) , we greatly reduced the number of convolution layers and filters (depth of network) for high speed processing. Our algorithm employs much fewer labels and features required for imaging processing than those for other typical CNN applications, such as autonomous driving. The unique feature of our algorithm is the ability to run two neural networks in parallel for two detection pathways: one for assay targets (e.g. microwells, beads, and fluorescence signals) and the other for defects. This allows the imaging processing to achieve high speed while maintaining good precision. As a result, it only took ~5 seconds (CPU: Intel Core i7-8700, GPU: NVIDIA Quadro P1000) to process two-color channel data for two 6000×4000 pixel images which contain 43561 micro-reactors. PEdELISA Microarray Platform Performance. To validate the effectiveness of the dual-pathway CNN method developed in this work, we compared its performance with that of the standard method based on global thresholding and segmentation (GTS). Figure 2A shows representative two-color-channel images causing errors to the image labeling and signal counting of the GTS method. These errors are corrected by the CNN method. For example, false signal counting derives from chip defects or poor labeling reagent confinements within individual microwell reactors due to the local failure of oil sealing. Defocusing can cause two neighboring microwells to be dilated with each other. Highly bright Qred fluorescence from an "On" microwell can cause secondary illumination to light up neighboring microwells. This results in "optical crosstalk" between neighboring microwells (28) , which causes the false counting of secondarily illuminated microwells as "On" sites. The uneven illumination of excitation light causes the failure of recognizing dim AF-488 encoded beads (recognized as non-color beads). In the CNN training process, we collected a large number of images for each error source and used them to train the neural network to achieve results similar to those from manual counting with the human eyes. We applied the following equation to evaluate the error in terms of deviation to the ground truth (%): (1) where NCNN or GTS is the number of microwell or bead counted either by CNN or GTS method respectively, NTP is the number of true positives determined by human labeling. The global threshold value was adjusted based on the gray histogram of the image ( Figure S4 ). The human labeling process includes the pre-processing with the GTS method together with human correction to obtain the ground truth, which has been validated by the conventional sandwich ELISA method in our previous study ( Figure S6 ) (26) . In counting enzyme active microwells with the Qred channel, we observed that the deviation percentage from ground truth varied with the number of the counted "On" (Qred+) microwells, which is proportional to the analyte concentration. Each data point in In counting color-encoded magnetic beads with the AF-488 channel, we found that the deviation was very small (CNN: 0.021%, GTS: 0.161%). The deviation was suppressed by the little spectral overlap between AF488 and Qred, channels and the high image contrast that we intentionally created between AF-488 and non-color encoded beads ( Figure 2C ). Some miscounting under the uneven spatial distribution of illumination light intensity and the spherical aberration of objective lens over the entire field of view still contributed to the deviation. The CNN method achieved a nearly 8-fold improvement of accuracy. Counting the total number of beads (both no color and fluorescence color-encoded ones) with brightfield images using a customized Sobel edge detection algorithm yielded an average deviation to the ground truth of 0.256% as shown in Figure 2D . To verify our ability to suppress optical crosstalk in the multiplexed assay incorporating the CNN method, we prepared a 25% fetal bovine serum (FBS) sample spiked with two different cytokine species of 1000-fold concentration difference: IL-1α (AF488 encoded) and IL-1β (non-color encoded). Optical crosstalk becomes problematic especially in multiplexed analysis, where the quantity of one biomarker can be serval orders of magnitude higher than those of other biomarkers in the same sample. A slightly false recognition can even give a significantly higher value of biomarker concentration than its true value. Figure 2E shows the comparison between the conventional GTS method and the CNN method. False recognition was greatly reduced by the CNN method and we verified that 1pg/mL of IL-1α or β will not interfere even when the other protein reaches 1ng/mL. Furthermore, we performed single-plexed measurements of 1pg/mL of IL-1α and IL-1β, which give "true" concentration values while eliminating optical crosstalk. The single-and dual-plexed measurements both yielded statistically similar results with the CNN method (two-tailed unequal variance t-test, IL-1α P=0.253; IL-1β=0.368), which proves the accuracy of this method even at the presence of strong optical crosstalk. Multiplex Pre-Equilibrium Cytokine Detection. Using 2-color encoded (AF488, noncolor) magnetic beads with 8 physically separated microarrays, we designed a microfluidic chip to detect 14 cytokines (up to 16-plex) simultaneously (see chip design in Figure S7 ). Figure 3A shows standard curves obtained from PEdELISA microarray analysis with CNN image processing for cytokines ranging from 0.16 pg/mL to 2.5 ng/mL in 25% FBS. Here, the measurement output is the fraction of the number of enzyme active (Qred+) beads to the total number of beads used for assaying the particular analyte. This fraction is directly correlated to the analyte concentration. The assay was performed for a system at the early state of a transient sandwich immune-complex formation reaction process with a 5-min incubation period, followed by a 1-min enzymatic labeling process. The reaction conditions have been optimized to match all cytokine biomarkers within the clinically relevant range, and a linear dynamic range of three orders of magnitude was achieved in general. Table S2 summarizes the values of the limit of detection (LOD) and limit of quantification (LOQ) of the assay for each cytokine. The antibody-antigen affinity affects the LOD of the assay, and it varies across the detected cytokine species. As a result, we obtained different LOD values for these cytokines even if the capture antibody-conjugated beads were prepared by the same protocol regardless of the analyte types (See Experimental Section). The LOD value tends to decrease with an increasing incubation period. Although the assay was performed with a short incubation period of 5 min, the LOD was found to be still below 5pg/mL (with IL-1β reaching the lowest 0.188pg/mL) after optimizing the detection antibody mixing ratio and the enzyme labeling concentration. We further assessed the level of antibody cross-reactivity among 14 cytokines in 25% FBS. Figure 3B shows the assay results for sera spiked by all, one, or none of the recombinant cytokines of 14 species, namely "all-spike-in," "single-spike-in," and "nospike-in" samples. We observed more than 100 times lower background signals from the no-spike-in (negative) sample than those from the all-spike-in sample across the 14 cytokines (except IL-17A for which there is a slightly higher background due to the more active binding between its capture and detection antibodies). The signal-level variation across the 14 cytokines at the same concentration from the all-spike-in and single-spike-in samples could derive from the different levels of analyte-antibody affinity for these cytokines. We also observed a similar trend in the variation of the LOD values for the cytokines from the curves in Figure 3A . Figure 4A shows that Patient 1 developed CRS on day 4 that persisted until day 9. We found significant elevations for all assayed cytokines on Day 0 in comparison to their baseline levels on Day -2 and Day -9. Interestingly, the spike on Day 0 is not due to the CAR-T cells, as the blood sample was taken prior to CAR-T infusion. Typically, CRS patients exhibit a high IL-6 concentration within their blood (35) . However, Patient 1 manifested a significantly higher level of TNF-α. This suggests biological heterogeneity in the pathogenic cytokine profiles of patients who develop CRS. We also conducted a similar analysis for a patient who did not develop CRS (Figure 4B) . We recorded an increase in IL-2 and a relatively high level of IL-17A for this patient, while other cytokines showed no significant changes throughout the analysis. Presumably, normal CAR-T cell expansion was taking place in the patient's body. We expect that extending the multiplex capacity of digital immunoassay would greatly broaden its utility in the continuous monitoring of protein biomarkers for critically ill patients. However, multiplexing the assay becomes enormously difficult with an increasing number of target biomarkers. Multiplexed digital signal counting required over more than a few millions of fL-sized reactors with conventional methods experiences poor sample/reagent handling and declined accuracy due to various error sources. In this study, we developed a highly multiplexed digital immunoassay platform, namely the PEdELISA microarray, to provide a promising solution for these challenges. The assay platform employs a unique combination of spatial-spectral encoding and machine learning-based image processing on a microfluidic chip. The positional registration of on-chip biosensing patterns, each with more than 40,000 microwell reactors confining sample sub-volumes, fluorescence-encoded analyte-capturing beads, and assay reagents, enabled 14-plex cytokine detection for 10 L of serum with high sample handling efficiency, small reagent loss, and negligible sensor cross talk. The signal processing and analysis of the 14-plexed PEdELISA microarray analysis employed a novel parallel computing CNN-based machine-learning algorithm. This algorithm achieved autonomous classification and segmentation of image features (e.g. microwells, beads, defects, backgrounds) at high throughput (1 min/analyte). Notably, it yielded 8-10-fold higher accuracy than the conventional GTS-based algorithm without any human-supervised error correction. We ran the PEdELISA microarray measurement of human serum samples from patients who received CAR-T cancer therapy with an incubation time as short as 5 min. The assay simultaneously detected 14 cytokine biomarkers per sample with a clinically relevant dynamic range of pM-nM, and the entire assay process from sample loading to data delivery was completed within 30 min. We tested blood samples obtained from a CAR-T patient at different time points during the course of the therapy with the short assay turnaround. The longitudinal measurement proved the ability of our assay platform to continuously monitor a large number of cytokine profiles that were rapidly evolving in the circulatory system of a patient manifesting CRS. With its speed, sensitivity, multiplexing capacity, and sample-sparing capability, the PEdELISA microarray is poised for future translation to critical care medicine, which is expected to allow the treatment of lifethreatening illnesses caused by emerging diseases (e.g., COVID-19) to be timely and tailored with the patient's comprehensive biomarker profiles. repeats to obtain the error bar. Group differences were tested using a two-tailed unequal variance t-test. A p-value of < 0.05 was considered to be statistically significant. The CAR-T patient cytokine data in this study is available through the database. All relevant data are available within the article file or Supplementary Information, or available from the authors on reasonable request. This arrangement yields Ncolor×Narray measurement combinations determining the assay plexity, Nplex, where Ncolor is the total number of colors used for encoding beads deposited in each biosensing pattern, and Narray is the total number of the arrayed biosensing patterns in each detection channel. In this study, Ncolor=2 (non-fluorescent and Alexa Fluor ® 488: AF488) and Narray=8. (B) A convolutional neural network-guided image processing algorithm for high throughput and accurate single molecule counting. Two neural networks were run in parallel, reading multi-color fluorescence image data, recognizing target features versus defects, and generating an output mask for post data processing. The brightfield image was analyzed using a Sobel edge detection algorithm. The images were finally overlaid to determine the fraction of enzyme active beads emitting QuantaRed TM signal (Qred+ beads) to total beads for each color label. The unlabeled scale bars are 25 μm. Image processing by convolutional neural network (CNN) and global thresholding and segmentation (GTS) methods (A) representative images causing false signal counting (red dot: Qred+ microwell, green dot: AF-488-colored bead, yellow dot: recognized spot to be counted). (i) The circle represents an area covered by an aqueous reagent solution that is spread over multiple microwell sites due to poor confinement during the oil sealing process. GTS counts potentially false and unreliable signal spots from the area. CNN removes the area from counting. (ii) Image defocusing causes GTS to merge two signal spots from a pair of the neighboring Qred+ microwells in the circle and to count it as a single signal spot. (iii) Secondary illumination of microwell sites due to optical crosstalk in the circle results in their false counting by GTS. (iv) GTS fails to label and count microwell sites holding dim AF-488-colored beads. Error analysis of CNN and GTS methods on (B) Qred-channel (C) AF488-channel and (D) brightfield images. (E) Tests assessing the impact of optical crosstalk on the accuracy of CNN and GTS using dual-color IL-1α and IL-1β detection by spiking (i) IL-1α:1ng/mL IL-1β:1ng/mL (ii) IL-1α:1ng/mL IL-1β:1pg/mL (iii) IL-1α:1pg/mL IL-1β:1ng/mL (iv) IL-1α:1pg/mL IL-1β:1pg/mL (v) IL-1α:1pg/mL IL-1β:1pg/mL assay in single plex for validation. All assays were performed in 25% fetal bovine serum buffer. The shaded region marks the period that the patient was diagnosed with grade 1-2 CRS. For better visualization, the data was organized and separately plotted based on the cytokine level from high to low. Biomarkers and Precision Medicine: State of the Art Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness The immunopathology of sepsis and potential therapeutic targets Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock Biomarkers of sepsis Diagnostic and prognostic biomarkers of sepsis in critical care Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia Highly Sensitive and Multiplexed Protein Measurements AC Electroosmosis-Enhanced Nanoplasmofluidic Detection of Ultralow-Concentration Cytokine Glass capillary based microfluidic ELISA for rapid diagnostics Time-Resolved Digital Immunoassay for Rapid and Sensitive Quantitation of Procalcitonin with Plasmonic Imaging An Integrated Plasmo-Photoelectronic Nanostructure Biosensor Detects an Infection Biomarker Accompanying Cell Death in Neutrophils Point-of-care sensors for the management of sepsis Biotunable Nanoplasmonic Filter on Few-Layer MoS2 for Rapid and Highly Sensitive Cytokine Optoelectronic lmmunosensing Integrated Biosensor for Rapid and Point-of-Care-Sepsis Diagnosis Multiplex Serum Cytokine Immunoassay Using Nanoplasmonic Biosensor Microarrays Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations Mobile platform for rapid sub-picogram-per-milliliter, multiplexed, digital droplet detection of proteins Digital Bioassays: Theory, Applications, and Perspectives Rapid single-molecule digital detection of protein biomarkers for near-real-time monitoring of systemic immune disorders A fully-automated, six-plex single molecule immunoassay for measuring cytokines in blood Multiplexed single molecule immunoassays A novel method based on a Mask R-CNN model for processing dPCR images A new method using machine learning for automated image analysis applied to chip-based digital assays Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Chimeric antigen receptor T-cell therapy -assessment and management of toxicities Current concepts in the diagnosis and management of cytokine release syndrome Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome The authors declare no conflict of interest.